Previous 10 | Next 10 |
Gainers: Checkmate Pharmaceuticals CMPI +333%. Petros Pharmaceuticals (PTPI) +55%. Axsome Therapeutics AXSM +23%. Avinger (AVGR) +11%. Processa Pharmaceuticals (PCSA) +10%. Losers: Lyra Therapeutics (LYRA) -16%. Diffusion Pharmaceuticals (DFFN) -15...
Gainers: Natus Medical (NTUS) +30%. MedAvail (MDVL) +25%. IMARA (IMRA) +13%. Frequency Therapeutics (FREQ) +11%. Lyra Therapeutics (LYRA) +4%. Losers: Nektar Therapeutics (NKTR) -36%. TG Therapeutics (TGTX) -24%. Lixte Biotechnology (LIXT) -15%....
Lyra Therapeutics Announces Closing of $100.5 Million Private Placement PR Newswire Private placement priced at-the-market under Nasdaq rules Proceeds to support Lyra's ongoing clinical development of LYR-210 and LYR-220 Proceeds, combined with existing...
Gainers: Biodesix (BDSX) +71%. Aeglea BioTherapeutics (AGLE) +37%. Rubius Therapeutics (RUBY) +9%. ASML Holding (ASML) +6%. Arcturus Therapeutics Holdings (ARCT) +5%. Losers: Lyra Therapeutics (LYRA) -6%. Hyzon Motors (HYZN) -5%. Paratek P...
Gainers: MedAvail (MDVL) +72%. Lyra Therapeutics (LYRA) +31%. TSR (TSRI) +24%. Biofrontera (BFRI) +18%. Takung Art (TKAT) +16%. Akanda (AKAN) +15%. Mullen Automotive (MULN) +16%. Nurix Therapeutics (NRIX) +14%. Borr Drilling (BORR) +14%. EPAM Systems (EPAM) +13%. Losers: Kaleid...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips We’re diving into the top penny stocks for today in our market update for Friday! Source: John Brueske/Shutterstock.com Before we get to the meat of this article, I’ve got to warn you about the potential...
Gainers: MedAvail MDVL +61%. Lyra Therapeutics LYRA +27%. Medicenna Therapeutics (MDNA) +25%. Biofrontera BFRI +23%. IsoPlexis (ISO) +8%. Losers: BioCryst Pharmaceuticals BCRX -33%. Sunshine Biopharma SBFM -33%. Werewolf Therapeutics (HOWL) -15%. I...
Lyra Therapeutics (NASDAQ:LYRA) to issue ~$100.5M securities in a private placement. Investors have an option to purchase either shares of the company's common stock at a price of $4.22 per share, or in lieu thereof, pre-funded warrants to purchase shares of the vompany's common stock, with a...
Lyra Therapeutics Announces $100.5 Million Private Placement PR Newswire WATERTOWN, Mass. , April 8, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) today announced that it has entered into a securities purchase agreement to sell securities in a priva...
Lyra Therapeutics press release (NASDAQ:LYRA): FY GAAP EPS of -$3.35 misses by $0.23. Cash and cash equivalents as of December 31, 2021 were $45.7 million, compared with $58.1 million as of September 30, 2021. Shares -1.18% PM. For further details see: Lyra Therapeutics GAAP EPS of -$3....
News, Short Squeeze, Breakout and More Instantly...
Lyra Therapeutics Inc. Company Name:
LYRA Stock Symbol:
NASDAQ Market:
Lyra Therapeutics Inc. Website:
WATERTOWN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patients with chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chi...
WATERTOWN, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced th...
-- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment in mid-2023 -- -- Data from BEACON Phase 2 Trial of LYR-220 in Post-Surgical CRS Anticipated Q4 2023 -- -- Advancing In-House Manufacturing Capabilities to ...